Keytruda (pembrolizumab) vs Ukoniq (umbralisib)

Keytruda (pembrolizumab) is an immune checkpoint inhibitor that works by blocking the PD-1 pathway, which helps the body's immune system to attack cancer cells, and is commonly used for various types of cancers, including melanoma, lung cancer, and head and neck cancer. Ukoniq (umbralisib) is a dual inhibitor of PI3K-delta and CK1-epsilon, which is used for treating certain types of lymphomas, such as marginal zone lymphoma and follicular lymphoma. When deciding between Keytruda and Ukoniq, it is crucial to consider the specific type of cancer being treated, as each medication has different indications and mechanisms of action, and the decision should be guided by a healthcare professional who can evaluate the individual's medical history and the specific characteristics of their cancer.

Difference between Keytruda and Ukoniq

Metric	Keytruda (pembrolizumab)	Ukoniq (umbralisib)
Generic name	Pembrolizumab	Umbralisib
Indications	Various types of cancers including melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and others	Marginal zone lymphoma (MZL) and follicular lymphoma (FL) after at least one prior anti-CD20-based regimen
Mechanism of action	Programmed death receptor-1 (PD-1) blocking antibody	PI3K delta and CK1 epsilon inhibitor
Brand names	Keytruda	Ukoniq
Administrative route	Injection (IV)	Oral
Side effects	Fatigue, musculoskeletal pain, decreased appetite, itching, diarrhea, nausea, rash, fever, cough, difficulty breathing, constipation	Nausea, diarrhea, fatigue, increased transaminases, musculoskeletal pain, anemia, thrombocytopenia, rash, neutropenia, and upper respiratory tract infection
Contraindications	None known; should be used with caution in patients with a history of severe immune-mediated adverse reactions	None known; should be used with caution in patients with severe hepatic impairment or severe renal impairment
Drug class	Anti-PD-1 monoclonal antibody	Small molecule kinase inhibitor
Manufacturer	Merck & Co.	TG Therapeutics

Efficacy

Keytruda (Pembrolizumab) Efficacy in Lymphoma

Keytruda, also known by its generic name pembrolizumab, is a type of immunotherapy that has shown efficacy in the treatment of certain types of lymphoma. It is a programmed death receptor-1 (PD-1) blocking antibody that helps the immune system to detect and fight cancer cells. Keytruda has been approved for use in patients with Hodgkin lymphoma who have relapsed or refractory disease after three or more prior lines of therapy. In clinical trials, pembrolizumab has demonstrated a significant response rate in this patient population, with many patients achieving partial or complete remission of their disease.

While the efficacy of Keytruda in non-Hodgkin lymphoma (NHL) is an area of active research, some studies have shown promising results in certain subtypes of NHL, such as primary mediastinal large B-cell lymphoma. However, the response rates and duration of response can vary depending on the specific type of lymphoma and previous treatments that the patient has undergone. It is important for patients to discuss with their healthcare provider whether Keytruda is an appropriate treatment option for their particular case of lymphoma.

Ukoniq (Umbralisib) Efficacy in Lymphoma

Ukoniq, with the active ingredient umbralisib, is a medication that targets specific signaling pathways in cancer cells. It is known as a PI3K delta inhibitor and is used in the treatment of certain types of lymphoma. Ukoniq has been approved for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based regimen and for adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy.

In clinical trials, umbralisib has shown a meaningful efficacy in these patient populations, with a considerable proportion of patients achieving objective responses. The duration of response and progression-free survival rates reported in these studies indicate that Ukoniq can be an effective treatment option for patients with these specific types of lymphoma who have limited treatment options due to the relapsed or refractory nature of their disease. As with any medication, the efficacy of Ukoniq can be influenced by various factors, including the patient's disease characteristics and prior treatments, and should be evaluated by a healthcare professional.

Regulatory Agency Approvals

Keytruda

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Therapeutic Goods Administration (TGA), Australia
Medsafe (NZ)

Ukoniq

Food and Drug Administration (FDA), USA

Access Keytruda or Ukoniq today

If Keytruda or Ukoniq are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Keytruda

Buy Ukoniq

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: